Search Result

Results for "

BMDM macrophages

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (1) Aminotransferases (Transaminases) (1) Apoptosis (1) c-Fms (1) CCR (1) Fluorescent Dye (1) GLUT (1) Glutathione S-transferase (1) IFNAR (1) Interleukin Related (4) NO Synthase (6) NOD-like Receptor (NLR) (2) OAT (1) PD-1/PD-L1 (1) PERK (1) PI3K (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) STAT (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) TRP Channel (1) URAT1 (1) VEGFR (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (2)

By Targets:

ADC Payload (1)

Akt (1)

Aminotransferases (Transaminases) (1)

Apoptosis (1)

c-Fms (1)

CCR (1)

Fluorescent Dye (1)

GLUT (1)

Glutathione S-transferase (1)

IFNAR (1)

Interleukin Related (4)

NO Synthase (6)

NOD-like Receptor (NLR) (2)

OAT (1)

PD-1/PD-L1 (1)

PERK (1)

PI3K (1)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

STAT (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

TRP Channel (1)

URAT1 (1)

VEGFR (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (6)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157131

TRPV2-selective blocker 1 2 Publications Verification	TRP Channel	Neurological Disease
TRPV2-selective blocker 1 is a TRPV2-selective blocker that inhibits calcium influx and ionic currents. TRPV2-selective blocker 1 exhibits an IC₅₀of 6.3 μM against rat TRPV2, and shows no activity against TRPV1, TRPV3 or TRPV4 channels. TRPV2-selective blocker 1 attenuates macrophage phagocytosis, LPS-induced macrophage migration, and calcium microdomains generated by peripheral TRPV2. TRPV2-selective blocker 1 is non-cytotoxic and can be used to investigate the function of TRPV2 during immune processes .

HY-B1076

Medrysone 1 Publications Verification HMS; 6α-Methyl-11β-hydroxyprogesterone	VEGFR CCR STAT	Neurological Disease
Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .

HY-158741

IPG-2 AM APG-2 Acetoxymethyl ester	Fluorescent Dye Potassium Channel	Others
IPG-2 AM (APG-2 Acetoxymethyl ester) is a membrane-permeant acetoxymethyl ester derivative and selective fluorescent potassium ion indicator. IPG-2 AM exhibits fluorescence increases proportional to extracellular potassium ion concentrations. IPG-2 AM enables real-time monitoring of cytosolic free potassium ion fluxes in human platelets and macrophages. IPG-2 AM can be used for the research of intracellular potassium concentration dynamics .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-P10383

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-175645

NLRP3/URAT1-IN-1	NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT	Metabolic Disease Inflammation/Immunology
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC₅₀ = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC₅₀ of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .

HY-N7697C

Chitohexaose hexahydrochloride	Toll-like Receptor (TLR) Interleukin Related Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Chitohexaose hexahydrochloride is a small molecular polysaccharide. Chitohexaose hexahydrochloride inhibits the binding of AgW to TLR4. Chitohexaose hexahydrochloride upregulates IL-10, inhibits LPS-induced upregulation of ROS, induces alternative activation of macrophages/monocytes, and suppresses LPS-induced production of TNF-α, IL-1β and IL-6. Chitohexaose hexahydrochloride reverses the mortality of mice challenged with APAP or LPS. Chitohexaose hexahydrochloride can be used in research related to Acetaminophen (HY-66005)-induced hepatotoxicity and endotoxemia .

HY-131040

NLRP3-IN-NBC6	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca ²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .

HY-W615446

GSTO1-IN-3	Glutathione S-transferase Interleukin Related	Inflammation/Immunology Cancer
GSTO1-IN-3 is a potent GSTO1-1 inhibitor with an IC₅₀ of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC₅₀ > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .

HY-128776

Antitumor agent-19	TNF Receptor	Cancer
Antitumor agent-19 is an antitumor agent that targets *tumor-associated macrophages* (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC₅₀** values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .

HY-P10384

SPSB2-iNOS inhibitory cyclic peptide-2	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .

HY-P10384A

SPSB2-iNOS inhibitory cyclic peptide-2 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .

HY-P10385A

SPSB2-iNOS inhibitory cyclic peptide-3 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-P10385

SPSB2-iNOS inhibitory cyclic peptide-3	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-149493

IHMT-PI3K-455	PI3K	Inflammation/Immunology Cancer
IHMT-PI3K-455 (Compound 15u) is a potent, selective, orally active PI3Kγ/δ dual inhibitor with IC₅₀s of 7.1 nM and 0.57 nM for PI3Kγ and PI3Kδ, respectively. IHMT-PI3K-455 suppresses the AKT phosphorylation. IHMT-PI3K-455 inhibits tumor growth by recruiting and activating more CD8 ⁺ killing T cells.IHMT-PI3K-455 is used in cancer research .

HY-P10383A

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-183569

CSF1R-IN-27	c-Fms Akt PERK Aminotransferases (Transaminases) Apoptosis TNF Receptor Interleukin Related	Metabolic Disease
CSF1R-IN-27 is a CSF1R inhibitor with oral effectiveness, kinome-wide selective profile, low cellular cytotoxicity, and CSF1R IC₅₀ values of 19 nM, 88 nM, 173 nM, 797 nM, 1448 nM, and >3000 nM. CSF1R-IN-27 suppresses M-CSF-induced phosphorylation of CSF1R, AKT, and ERK in macrophages, and inhibits hepatic p-CSF1R/p-AKT/p-ERK signaling. CSF1R-IN-27 reduces serum transaminase levels, improves hepatic histopathology, alleviates inflammatory cell infiltration, and decreases circulating TNF-α and IL-6 levels. CSF1R-IN-27 can be used for the research of acute liver injury .

Cat. No.	Product Name	Type

HY-158741

IPG-2 AM APG-2 Acetoxymethyl ester	Fluorescent Dyes
IPG-2 AM (APG-2 Acetoxymethyl ester) is a membrane-permeant acetoxymethyl ester derivative and selective fluorescent potassium ion indicator. IPG-2 AM exhibits fluorescence increases proportional to extracellular potassium ion concentrations. IPG-2 AM enables real-time monitoring of cytosolic free potassium ion fluxes in human platelets and macrophages. IPG-2 AM can be used for the research of intracellular potassium concentration dynamics .

IPG-2 AM

APG-2 Acetoxymethyl ester

Fluorescent Dyes

IPG-2 AM (APG-2 Acetoxymethyl ester) is a membrane-permeant acetoxymethyl ester derivative and selective fluorescent potassium ion indicator. IPG-2 AM exhibits fluorescence increases proportional to extracellular potassium ion concentrations. IPG-2 AM enables real-time monitoring of cytosolic free potassium ion fluxes in human platelets and macrophages. IPG-2 AM can be used for the research of intracellular potassium concentration dynamics .

Cat. No.	Product Name	Target	Research Area

HY-P10383

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-P10384

SPSB2-iNOS inhibitory cyclic peptide-2	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .

HY-P10384A

SPSB2-iNOS inhibitory cyclic peptide-2 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .

HY-P10385A

SPSB2-iNOS inhibitory cyclic peptide-3 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-P10385

SPSB2-iNOS inhibitory cyclic peptide-3	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

HY-P10383A

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

Chitohexaose hexahydrochloride	Structural Classification Animals Classification of Application Fields Inflammation/Immunology Disease Research Fields Saccharides Source Classification	Toll-like Receptor (TLR) Interleukin Related Reactive Oxygen Species (ROS)
Chitohexaose hexahydrochloride is a small molecular polysaccharide. Chitohexaose hexahydrochloride inhibits the binding of AgW to TLR4. Chitohexaose hexahydrochloride upregulates IL-10, inhibits LPS-induced upregulation of ROS, induces alternative activation of macrophages/monocytes, and suppresses LPS-induced production of TNF-α, IL-1β and IL-6. Chitohexaose hexahydrochloride reverses the mortality of mice challenged with APAP or LPS. Chitohexaose hexahydrochloride can be used in research related to Acetaminophen (HY-66005)-induced hepatotoxicity and endotoxemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

BMDM macrophages

Inhibitors & Agonists

Fluorescent Dyes

Peptides

NaturalProducts

Natural
Products